Direct regulators | Interaction location | Upstream pathway(s) | Reference(s) |
---|---|---|---|
LOXL2/3 | SNAG domain; K98 and K127 | Notch/Lox | [17] |
NF-κB | Promoter: -194 to -78 bp | TNFα, RANKL, PI3K/Akt | |
HIF-1α | Promoter: -750 to -643 bp | Hypoxic conditions | [19] |
SMADs | Promoter: -631 to -506 bp | TGF-β1, Ras | |
IKKα | Promoter: -631 to -506 bp (concurrent with SMADs) | TGF-β1, Ras, PI3K/Akt | |
HMGA2 | Promoter: 2 regions within -131 to -92 bp | TGF-β1 | [22] |
YY1 | 3 Enhancer | NF-κB | [30] |
Egr-1 | Promoter: 4 sites between -450 and -50 bp | HGF, MAPK | [29] |
PARP-1 | Promoter: SIRE | ILK | [23] |
Gli1 | There are 4 candidate GLI binding sites (consensus sequence for binding: 5'-GACCACCCA-3') | Shh, Wnt | [26] |
STAT3 | Promoter | IL-6/JAK, HB-EGF/EGFR/MEK/ERK (mice) | |
MTA3 | Promoter | ER | |
PAK1 | S246 | Â | [36] |
GSK-3β | Motif 1 (S96, S100, S104) and Motif 2 (S107, S111, S115, S119) | Wnt, PI3K/Akt, FGF | |
Snail1 | Promoter: E box within SIRE | Binds to own promoter | [31] |